11thAlzheimer's and Parkinson's Drug Development Summit (description)


Address:555 North Point Street San Francisco, California, United States of America 94133
Phone:+1 617 455 4188
Event dates:2/21/2023 - 2/23/2023 (This event has already taken place)
Event web site:
findCE GPA: This event is not yet rated. Click here to view a sample report card
Click here to rate 11thAlzheimer's and Parkinson's Drug Development Summit


Topics to be Covered:

  • Rachel Angers Associate Director, Neurodegeneration UCB
  • Sandra Banack Senior Scientist Brain Chemistry Labs
  • Habib Baghirov Scientific Lead Roche
  • Jay Barth Executive Vice President and Chief, Medical Officer Lexeo Therapeutics
  • Science, Health and Medicine
  • Pharmaceuticals
  • Drug Development
Organizer phone:+1 617 455 4188
Offering type:Conference
Specialty:Data not provided
Event frequency:Never
First Meeting:
Total events:
Est. attendance:
Target audience:Any
Other target audiences:
Host Sponsor:Hanson Wade
Est. # of exhibitors:
Currency:US Dollars
Language:Data not provided
CE Credits:
Organizer URL


With a surge in preclinical investment, fresh news of clinical pipeline progressions, and a new era of therapies pending FDA approvals from Biogen, Eisai, and Denali Therapeutics, 2022 has put neurodegenerative drug development back on the map.

Building on the field's momentum, we are delighted to bring back the 11th Alzheimer's and Parkinson's Drug Development Summit, dedicated to overcoming the translational challenges of targeting neurodegenerative mechanisms. This summit will unite neurodegenerative biopharma experts from discovery, preclinical, translational, and clinical backgrounds to showcase the latest breakthroughs in Alzheimer's, Parkinson's, and related neurological disorders in 2022 and 2023.

Speakers: Karen He Scientist, Disease Genetics Janssen, Tien Dam Executive Medical Director - Neurodegeneration Development Unit, Head of Movement Disorders Biogen, Cheng Fang Senior Vice President, Research and Development Annovis Bio, Sarah Huntwork-Rodriguez Associate Director, Biomarkers Denali Therapeutics Inc., Dimitrios Kapogiannis Senior Investigator, Chief of Human Neuroscience Section NINDS/NIH, Henri Huttunen Chief Scientific Officer Herantis Pharma Plc, Judith Kelleher-Andersson Chief Executive Officer and President Neuronascent, Sam Jackson Chief Medical Officer Neuron23, Viktoria Kheifets Senior Vice President Alkahest, Jeffrey Kordower Professor and Founding Director, ASU-Banner Neurodegenerative Disease Research Center Rush University Medical Center, Justine Manos Principal Research Scientist II Abbvie Inc., Rouba Kozak Global Biomarker Diagnostic and Neuroscience Lead Novartis AG, Meriel Owen Associate Director, Search and Evaluation Alzheimer's Drug Discovery, Jacob Marcus Director Merck and Co, Luis Miguel Oliveira Senior Associate Director - Research Programs The Michael J. Fox Foundation for Parkinson's Research, Bruce Morimoto Vice President, Drug Development Alto Neuroscience, Ryan Schubert Senior Vice President Translational Medicine and Clinical Strategy ASCENEURON, Andrea Small-Howard President and Chief Science Officer GrowBlox Sciences OTCQB, Ana Cristina Puhl Associate Director Collaborations Pharmaceuticals Inc., Anindya Sen Executive Director Prevail Therapeutics, Milton Werner President and Chief Scientific Officer Inhibikase Therapeutics, Steve Stice Co-Founder and Chief Scientific Officer ArunA Bio, Gregory Stewart Consultant Alcyone Life Sciences, Diane Stephenson Executive Director, Critical Path for Parkinson's Critical Path Institute, Gayle Wittenberg Vice President - Neuroscience Data Science and Digital Health Johnson and Johnson Services, Inc, Jian Yang Associate Vice President, Digital Health Research and Development Eli Lilly and Co., Hiu Zhang Senior Director Eli Lilly and Co.


09:00 - 17:30

Registration Fee Details:

Conference + Pre-Conference Workshop Day - Drug Developer: USD 4946.00,
Conference + Novel CNS Biomarker Day - Drug Developer: USD 4946.00,
Conference Only - Drug Developer: USD 2999.00,
Conference + Pre-Conference Workshop Day - Service Provider Pricing: USD 5846.00,
Conference + Novel CNS Biomarker Day - Service Provider Pricing: USD 5846.00,
Conference Only - Service Provider Pricing: USD 3599.00

Other items that tuition includes:

Travel and hotel arrangements:

Contact Person:Erin Thomas
Organizer State/Province: (Outside US)
Organizer CountryData not provided
Organizer Phone+1 617 455 4188
Structural makeupData not provided
Host Sponsor; Other SponsorsHanson Wade
Event Site/VenueHyatt Centric Fisherman's Wharf San Francisco
Event sold out?No
Multiple locations or dates?No
Statistics available for most recent event held in:NA
Average number in event attendance of:
Number in attendance of:
total attendance #: 1000
Target BoundariesInternational
Is Registration contact information the same as Organizer Contact above?Yes
Web Page
Can one register for your CE on your web site?NA
Can registration be made by snail (regular) mail?Yes
Online housing reservations: 
Do you have additional written or AV materials for sale?No
If so, are they available for non-attendees as well as those attending?NA
Is full tuition necessary to ensure registration?No
Will there be shuttle service available?NA
Additional notes:


Sign In/Sign Out
About Us
Contact Us